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Abstract
Objective:  To determine the prevalence of, and patient characteristics associated with,
antiplatelet therapy in a cohort of primary care patients with Type 1 or Type2 diabetes.
Methods:  Subjects participating in a randomized trial of a decision support system were
interviewed at home and medication usage verified by a research assistant. Eligibility for antiplatelet
therapy was determined by American Diabetes Association criteria and clinical contraindications.
The association between antiplatelet use and patient characteristics was examined using bivariate
and multivariate logistic regression.
Results: The mean age of subjects was 64 years (range 31–93). The prevalence of antiplatelet use
was 54% overall; 45% for subjects without known CVD vs. 78% for those with CVD; 46% for
women vs. 63% for men; and 45% for younger subjects (age< 65) vs. 62% for senior citizens. After
controlling for race/ethnicity, income, education, marital status, insurance status and prescription
coverage, the following were associated with the use of antiplatelet therapy: presence of known
CVD (OR 3.4 [2.2, 5.1]), male sex (OR 2.0 [1.4, 2.8]), and age > = 65 (OR 1.9 [1.3, 2.7]). The
prevalence of antiplatelet therapy for younger women without CVD was 32.8% compared to a
prevalence of 90.3% for older men with CVD.
Conclusion: Despite clinical practice guidelines recommending antiplatelet therapy for patients
with diabetes, there are still many eligible patients not receiving this beneficial therapy, particularly
patients under 65, women, and patients without known CVD. Effective methods to increase
antiplatelet use should be considered at the national, community, practice and provider level.
Introduction
Cardiovascular disease (CVD) is the leading cause of mor-
bidity and mortality in adults with diabetes [1-4].
Antiplatelet therapy, with either aspirin or the newer
platelet aggregation inhibitors, has been shown to be safe
and cost effective for reducing the risk of recurrent vascu-
lar events [5-8]. Consensus guidelines recommend the use
of antiplatelet therapy for both primary and secondary
prevention of CVD [9,10]. In 1997, the American Diabe-
tes Association (ADA) recommended antiplatelet therapy
for adults with diabetes and co-existing CVD, and for
adults with diabetes over 30 years of age, even in the
absence of CVD [11]. Prior to the publication of the ADA
recommendations for antiplatelet prophylaxis, the
national rate of aspirin use among patients with diabetes
was estimated at 13% for individuals without CVD and at
37% for those with CVD [12]. By 2001 this latter preva-
lence, as determined by telephone survey, had increased
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to 48.7% [13]. Current estimates suggest that approxi-
mately 5% of adults cannot tolerate aspirin therapy. For
these individuals, an alternative antiplatelet agent may be
used [14].
Despite increasing evidence to support its effectiveness
among patients with diabetes, antiplatelet therapy has
been under-utilized [12,15,16], particularly in women
[13]. While several observational studies have examined
the prevalence of aspirin use both before and after the
publication of the 1997 ADA recommendations, none
have included the use of other antiplatelet agents and may
therefore have underestimated the prevalence of
antiplatelet therapy. The goal of this study is to determine
the prevalence of antiplatelet therapy (aspirin and newer
platelet aggregation inhibitors) for both primary and sec-
ondary prevention of CVD in diabetes and to examine the
patient characteristics that are associated with failure to
use this important therapy.
Methods
This study was part of a larger project, the Vermont Diabe-
tes Information System (VDIS), a cluster-randomized trial
of a laboratory-based diabetes decision support system in
Table 1: VDIS Subjects Eligible for Antiplatelet Therapy (N = 785)
Characteristic N Mean or Prevalence
Female 435 55%
Age, mean (SD) (range) 785 64 (11.8) (31–93)
Age > = 65 395 50%
Race/Ethnicity
White, non-Hispanic 764 97.6%
Education
High school graduate 599 77%
Marital Status
Married or living as married 503 64%
Current smoker 125 16%
Endocrinology consult visit in past year 122 16%








< $30,000 407 56.4%
Body Mass Index
Normal (< 25) 85 10.9%
Overweight (25–29.9) 182 23.4%
Obese (> = 30) 510 65.6%
Very Obese (> = 40) 141 18.2%
Cardiovascular Disease §
Any CVD 206 26.2%
Myocardial Infarction 127 16.2%
Stroke 68 8.7%
Peripheral Vascular Disease 61 7.8%
Number of prescription medications, mean (SD) 785 6.2 (3.5)
Number of MD visits in previous year, mean (SD) 785 1.5 (2.2)
Years since diagnosis of DM, mean (SD) 785 9.9 (10.1)
Antiplatelet therapy (aspirin or other) 421 53.6%
Aspirin only 371 47.3%
Non-aspirin platelet aggregation inhibitor only 20 2.5%
Aspirin and platelet aggregation inhibitor 30 3.8%
Antiplatelet therapy if known CVD 206 78.2%
* Subjects may have more that one type of insurance coverage
§Subjects may have more than one type of CVDCardiovascular Diabetology 2005, 4:18 http://www.cardiab.com/content/4/1/18
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a region-wide sample of 7295 adults with diabetes from
55 community Primary Care practices [17]. We did not
distinguish between Type 1 and Type 2 diabetes because
this distinction is not clinically important when recom-
mending antiplatelet therapy. A field survey targeted at a
sub-sample of subjects was designed to provide a better
understanding of the non-laboratory features of diabetes.
Patients were selected at random from the subjects in each
practice participating in the VDIS trial and invited by
phone to participate in an in-home interview. Patient
names were randomly sorted and patients contacted by
telephone until a sample of approximately 15% of the
patients from each practice agreed to an interview. We
attempted to contact 4209 patients and reached 1576. Of
these, 1006 agreed to be interviewed. Demographic infor-
mation including age, sex, race, ethnicity, education,
income, marital status and history of cardiovascular dis-
ease were obtained by questionnaire. A complete list of
medications was obtained by a research assistant by direct
observation of all of the medication containers and
recording of the medication name, dose, frequency and
route of administration. The interviews occurred between
July 2003 and March 2005. The University of Vermont
Institutional Review Board approved the study and all
subjects gave written informed consent to participate in
the interview.
For the purposes of this cross-sectional study, a subset of
interviewed subjects was created using inclusion and
exclusion criteria based on the current American Diabetes
Association (ADA) recommendations for the use of
antiplatelet therapy [18]. The subset of subjects who were
eligible for antiplatelet therapy consisted of all subjects in
the VDIS interview cohort 30 years or older, and those
under 30 years with a self-reported history of either coro-
nary heart disease, stroke or transient ischemic attack, or
peripheral vascular disease. For the purposes of the study
we defined cardiovascular disease (CVD) as any of the
above manifestations of vascular disease. We excluded
patients with specific contraindications to antiplatelet
therapy: peptic ulcer disease (144), severe liver disease
(13), and those on current warfarin therapy (75), for
whom decisions about concomitant use of antiplatelet
therapy and anticoagulation would be individualized. No
information was available about side effects or previous
discontinuation of therapy was available. Some subjects
had more than one exclusion; a total of 221 subjects were
excluded for a final sample of 785 subjects. Antiplatelet
Table 2: Bivariate Associations with Anti-Platelet Use in Adults with Diabetes
Characteristic Odds Ratio [95% CI] P Value
Male sex 2.0 [1.5, 2.7] <0.001
Age > 65 years 2.0 [1.5, 2.6] <0.001
Race/ethnicity, White, non-Hispanic 2.0 [0.8, 5.2] 0.15
Education: > HS graduate 0.8 [0.6, 1.1] 0.25
Married or living as married 1.0 [0.8, 1.4] 0.84
Smoker 0.8 [.05, 1.1] 0.16
Endocrinology consult within 1 year 1.8 [1.2, 2.7] 0.004
Diabetes education class within 1 year 1.4 [1.0, 2.0] 0.06
Insurance category
None 0.28 [0.10, 0.78] 0.02
Private 1.15 [0.86, 1.53] 0.35
Medicare 1.88 [1.40, 2.51] <0.001
Medicaid 0.98 [0.68, 1.4] 0.91
Military 1.78 [0.85, 3.70] 0.13
Income < $30,000 1.1 [0.8, 1.5] 0.55
Prescription coverage 0.9 [0.7, 1.1] 0.19
Body Mass Index
BMI category (normal, overweight, obese) 0.8 [0.7, 1.0] 0.11
Obese (BMI > 30) 0.8 [0.6, 1.0] 0.07
Severe Obesity (BMI > 40) 0.6 [.04, 0.9] 0.01
Type of Cardiovascular Disease
Any CVD 3.3 [2.4, 4.3] <0.001
Myocardial Infarction 6.7 [4.0, 11.3] <0.001
Stroke 2.1 [1.2, 3.5] 0.008
Peripheral Vascular Disease 3.1 [1.7, 5.8] <0.001
Number of PCP visits in previous month 1.04 [0.97, 1.11] 0.26
Duration of diabetes (in years) 1.01 [1.00, 1.03] 0.13Cardiovascular Diabetology 2005, 4:18 http://www.cardiab.com/content/4/1/18
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use was defined as daily use of aspirin (at least 75 mg/
day); clopidogrel; ticlodipine; or cilostazol; or a combina-
tion of aspirin and clopidogrel, ticlodipine, or cilostazol
daily. The specific indication for the anti-platelet agent in
each subject was not known.
We used logistic regression to test the bivariate association
of anti-platelet use with variables that were potentially
important based on previous research and clinical judg-
ment, including age, sex, race/ethnicity, income, educa-
tion, marital status, insurance status and pharmacy
benefits, years since diagnosis of diabetes, smoking, body
mass index, frequency of visits to primary care physician,
specialist involvement in care (endocrinologist visit in the
last year, attendance at a diabetes education class within
the last year), and the various categories of CVD. Variables
that demonstrated an association in bivariate modeling at
a significance level of p < 0.1 were further examined with
multivariate regression modeling in which insignificant
(p > 0.05) variables were eliminated in a backward step-
wise fashion.
Results
The characteristics of the study population are presented
in Table 1. The mean age was 64 years with half the pop-
ulation over age 65. Most graduated high school and
fewer than 3% were uninsured. Most subjects were over-
weight or obese (89%), with 18% falling in the severely
obese category (body mass index of 40 or greater).
Twenty-six percent of the population had cardiovascular
disease, with myocardial infarction being the most com-
mon manifestation in 16%.
The prevalence of antiplatelet use was 53.6% (47.3% aspi-
rin alone, 2.5% newer platelet aggregation inhibitor and
3.8% both) for all eligible subjects and 78.2% for subjects
with known CVD. The characteristics associated with
antiplatelet medication use are noted in Table 2. Male sex
and older age are both associated with a two-fold increase
in antiplatelet use (p < 0.001). Cardiovascular disease was
associated with a three-fold increase in antiplatelet use,
with MI showing a six-fold increase (p < 0.001). Other fac-
tors that were associated with anti-platelet agent use were:
an endocrinology visit in the previous year (p = 0.004),
and Medicare insurance coverage (p < 0.001).
In multivariable analysis, three characteristics remained
independently associated with antiplatelet use while con-
trolling for important covariates (see Table 3). Subjects
with a history CVD were more likely to be on appropriate
antiplatelet therapy (OR 3.4 [CI 2.2, 5.1]), as were sub-
jects 65 or older (OR 1.9 [CI 1.3, 2.7]) and men (OR 2.0
Table 3: Multivariate Model of Characteristics Associated with Anti-Platelet Use in Adults with Diabetes*
Characteristic Odds Ratio [95% CI] P Value
CVD history 3.4 [2.2, 5.1] <0.001
Senior (age > 65) 1.9 [1.3, 2.7] <0.001
Male sex 2.0 [1.4, 2.8] <0.001
*Controlling for race, income, education, marital status, insurance, prescription coverage
Table 4: Prevalence of Antiplatelet Use by Patient Characteristic
Sex Age % on Antiplatelet therapy N
CVD Absent Female Less than 65 33% 180
65 or older 45% 151
Male Less than 65 49% 137
65 or older 60% 111
CVD Present Female Less than 65 58% 33
65 or older 77% 70
Male Less than 65 78% 41
65 or older 90% 62Cardiovascular Diabetology 2005, 4:18 http://www.cardiab.com/content/4/1/18
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[CI 1.4, 2.8]), (p < 0.001 for each). Table 4 indicates the
prevalence of antiplatelet use in each of these patient sub-
groups. The lowest rates are among women under 65
without CVD (32.8%), and highest among older men
with known CVD (90.3%).
Among the 206 subjects with known CVD we found sim-
ilar associations with antiplatelet use with age > 65 (OR
3.0 CI [1.4, 6.3]), and male sex (OR 3.3 [1.5, 7.1]).
Discussion
We found a prevalence of antiplatelet therapy use among
adults with diabetes of 53.6% (47.3% aspirin alone, 2.5%
newer platelet aggregation inhibitor and 3.8% both),
which is similar to the recent nationally representative tel-
ephone survey estimate of aspirin use of 48.7% by Persell
[13]. Among patients with CVD we found a prevalence of
antiplatelet therapy of 78.2%, compared to 74.2% by
Persell [13].
We found the highest rates among subjects with CAD. Fol-
lowing the CAPRIE trial in 1996, which showed a slight
advantage in secondary prevention of cardiovascular
events for clopidogrel vs. aspirin, clopidogrel has been
increasingly used both in addition to aspirin and as its
replacement [19,20]. The newer platelet aggregation
inhibitors are also increasingly used for acute coronary
syndrome and after percutaneous coronary intervention
[21]. The strong evidence for CAD indications is reflected
in our findings that subjects with coronary artery disease
were the most likely to be receiving antiplatelet therapy.
Our motivation in exploring the factors associated with
antiplatelet agent use was to help identify subgroups that
may be targeted for special efforts to increase antiplatelet
therapy. We found that women, patients younger than 65,
and those without CVD were less likely to be using
antiplatelet therapy. On the other end of the spectrum,
over 90% of men over 65 with CVD were taking antiplate-
let therapy. This high level of use among those at the high-
est risk supports the achievability of the consensus
guidelines. A recent meta-analysis including 287 studies
and 135,000 patients at high vascular risk showed that
antiplatelet therapy reduced serious vascular events (non-
fatal MI, non-fatal stroke, vascular death) by 36 (SE 5) per
1000 patients treated for two years [22]. Assuming that we
can move from our overall prevalence of antiplatelet ther-
apy of 54% to our best rate of 90%, we estimate that
another 13 serious vascular events per 1000 could be
averted over two years. If this is projected to the 18.2 mil-
lion adults with diabetes in the United States [23], we esti-
mate that 238,000 serious vascular events could be
averted.
Why are patients with diabetes not receiving antiplatelet
therapy despite consensus guidelines? First of all, prescrib-
ers may feel there is some ambiguity regarding the role of
aspirin in CVD primary prevention for patients with dia-
betes. For example, while the Primary Prevention Project,
which randomized over 4000 diabetic and non-diabetic
subjects with CVD risk factors to aspirin or no aspirin, was
stopped early because of the beneficial effects of aspirin,
in the subgroup with diabetes the benefits were smaller
and not statistically significant. [24] This raises the ques-
tion of potential differences in the role of antiplatelet ther-
apy in diabetes. Secondly, even if prescribers agree with
the guideline, there are other barriers to achieving perfect
compliance. A qualitative study exploring reasons cited by
physicians for not prescribing aspirin included: difficul-
ties in applying generic guidelines to individuals, patient
resistance to taking aspirin, prioritization of other issues
in a time constrained visit, and communication problems
in reviewing the medications of patients with stroke [25].
Why might women be less likely to be receiving antiplate-
let therapy? Gender differences have been well docu-
mented in the diagnosis and treatment of heart disease
[26] In addition, the effects of aspirin may be different in
men and women; a recent study of primary prevention of
CVD in almost 40,000 women over 45 years of age
showed that, while stroke risk was lowered, myocardial
infarction and overall cardiovascular mortality were not
[27]. Physicians may be less enthusiastic about the evi-
dence base supporting the use of antiplatelet therapy in
women. For patients under age 65, physicians (and
patients themselves) may not perceive the risks of CVD as
high enough to warrant antiplatelet therapy.
We observed an association between the use of antiplate-
let therapy and the type of CVD. Patients with a history of
prior myocardial infarction were more likely to be on
antiplatelet therapy (86%) than those with a history of
peripheral vascular disease (77%) or cerebrovascular acci-
dent (CVA) (69%). Furthermore, only 54% of patients
with CVA and no other CVD were using an antiplatelet
agent. Antiplatelet therapy has been shown to reduce the
risk of recurrent CVA by 11% to 15% in patients with
prior ischemic stroke of non-cardiac origin and reduce the
risk of stroke, MI, and vascular death, by 22% [28]. The
extent to which stroke patients and their physicians avoid
antiplatelet therapy due to risk of bleeding is not known.
This lower use of antiplatelet therapy in stroke patients
identifies an area for potential investigation and interven-
tion to improve anti-platelet regimens in this patient pop-
ulation.
Health insurance coverage has been shown to be an
important factor in the delivery of medical services.
Increasing levels of health insurance have a positive corre-Cardiovascular Diabetology 2005, 4:18 http://www.cardiab.com/content/4/1/18
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lation with the likelihood that an individual will receive
appropriate preventive care [29]. In diabetes, poor insur-
ance coverage has been associated with delayed or omit-
ted preventive services [30]. We found that health
insurance coverage was not an important predictor of
anti-platelet therapy in patients of this cohort, but the
level of health insurance coverage was high and subjects
were under the care of a primary care provider suggesting
good access to care. In the case of an expensive medicine
like clopidogrel, lack of prescription drug coverage could
contribute to lack of use. However, aspirin, which com-
prises the majority of the antiplatelet agents in our study,
is a low cost, nonprescription medication.
This study has several limitations. Our population, while
representative of patients receiving primary care in the
rural Northeast may not be representative of all adults
with diabetes in the U.S. We do not have information
regarding allergies or side effects associated with antiplate-
let medications. It is possible that eligible subjects were
unable to tolerate therapy, though it is unlikely this would
be the case in more than 5% of subjects. It is unlikely that
medication intolerance would be correlated with age, sex
or cardiovascular disease. We do not have information
regarding the indication for aspirin use, though 98% of
subjects reported low-dose aspirin use (< = 325 mg/d)
suggesting prophylaxis. Our analysis does not indicate
causality and the exact mechanisms promoting or deter-
ring the use of recommended interventions is unknown.
There have been a variety of successful interventions
directed at increasing the use of antiplatelet therapy for
the prevention of CVD including: HMO-directed quality
improvement efforts [31], intensive multifaceted case
management [32], pharmacy-directed interventions
[33,34], and electronic medical record reminder systems
[35]. A VA study found that physician counseling was
highly associated with antiplatelet therapy and suggested
that this simple intervention could prevent many cardio-
vascular events and deaths [36]. There are many ways in
which antiplatelet use can be increased; it is now a ques-
tion of which approach can be most efficiently adapted in
each clinical setting.
Conclusion
Despite clinical practice guidelines recommending
antiplatelet therapy for patients with diabetes, there are
still many eligible patients not receiving this beneficial
therapy, particularly patients under 65, women, and
patients without known CVD. Effective methods to
increase antiplatelet use should be considered at the
national, community, practice and provider level.
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